US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

25.94

-0.8443-3.15%

Post-market: 25.940.00000.00%16:04 EDT

Volume:95

Turnover:2K

Market Cap:2.33M

PE:- -

High:25.94

Open:26.79

Low:25.94

Close:26.79

52wk High:28.33

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.31

T/O Rate:0.11%

Dividend:0.24

Dividend Rate:0.91%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Corbus reports last patient completes last visit in CANYON-1 trial

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026

Fresenius announces FDA approval of rituximab biosimilar

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Press Release: Design Therapeutics Provides Restore-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares

Press Release: Radiopharm Theranostics Reports Business Update

Shenzhen Chipscreen Biosciences Gets China Clinical Trial Approval for Leukemia Tablets

MT Newswires Live

Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances

PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year

Clearmind Medicine announces safety results from Part A of CMND-100 tral

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NVIB/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":25.9412,"timestamp":1787601600000,"preClose":26.7855,"halted":0,"volume":95,"hourTrading":{"tag":"盘后","latestPrice":25.9412,"preClose":25.9412,"latestTime":"16:04 EDT","volume":4,"amount":103.7648,"timestamp":1787601854370,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03152078549961735,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Post-Mkt","change":-0.8443,"latestTime":"08-24 17:14:05 EDT","open":26.7855,"high":25.9412,"low":25.9412,"amount":2477,"amplitude":0,"askPrice":39.28,"askSize":200,"bidPrice":13.1,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":26.7855,"nav":26.758,"aum":2408282.49,"dividendRate":0.009074,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.9412,"preClose":25.9412,"latestTime":"16:04 EDT","volume":4,"amount":103.7648,"timestamp":1787601854370,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.307642},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.307642,"shares":90001,"dividePrice":0.2354,"high":25.9412,"amplitude":0,"preClose":26.7855,"low":25.9412,"week52Low":24.54,"pbRate":"--","week52High":28.3265,"institutionHeld":0,"latestPrice":25.9412,"eps":0,"divideRate":0.009074,"volume":95,"delay":0,"ttmEps":0,"open":26.7855,"prevYearClose":25,"prevWeekClose":26.7855,"prevMonthClose":25.6004,"prevQuarterClose":25,"fiveDayClose":28.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657460636","title":"Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657460636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657460636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"--  Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) ----  Completed sale of sevasemten and musc","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4531","BK4588","GDOC","BK4007","BK4585","BMED","HYLG","IDNA","NVIB","EWTX","MEDX","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","BK4588","MRNX","TECB","IDNA","GDOC","MRNY","IEIH","MEDI","TBXU","SYNB","LABU","PINK","XLVX","BK4585","IYH","IBB","BMED","BBP","GNMX","RSPH","PSCH","FRTY","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657764305","title":"Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657764305","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657764305?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:05","pubTimestamp":1785960300,"startTime":"0","endTime":"0","summary":"Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027Enrollment also ongoing for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339675/0/en/Biomea-Fusion-Reports-Second-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","NVIB","BMEA","GDOC","HYLG","IDNA","JDOC","BK4585","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657678575","title":"OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657678575","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657678575?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:05","pubTimestamp":1785873900,"startTime":"0","endTime":"0","summary":"-- Executing IND-enabling activities for next-generation PI3Kαpan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Ho","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338800/0/en/OnKure-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","GDOC","BK4539","LENZ","MEDX","IDNA","BK4139","HYLG","BK4007","NVIB","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656967554","title":"Corbus reports last patient completes last visit in CANYON-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656967554","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656967554?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:55","pubTimestamp":1785851749,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (CRBP) announced the last patient has completed their last clinical visit in the company’s CANYON-1 Phase 1b clinical trial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","BK4139","CRBP","HYLG","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656564305","title":"IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2656564305","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656564305?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:00","pubTimestamp":1785844800,"startTime":"0","endTime":"0","summary":"LAWRENCEVILLE, N.J., Aug.  04, 2026  (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338235/0/en/IMUNON-to-Hold-Second-Quarter-2026-Financial-Results-and-Business-Update-Conference-Call-on-Tuesday-August-11-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","NVIB","HYLG","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304376","title":"Fresenius announces FDA approval of rituximab biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304376?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:15","pubTimestamp":1785788150,"startTime":"0","endTime":"0","summary":"Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","MRNX","SYNB","MEDI","RSPH","FSNUY","IDNA","BK4588","BBP","IEIH","LABU","LFSC","BMED","GNMX","GDOC","FRTY","TBXU","TECB","NVIB","PINK","IBB","BK4585","MRNY","IYH","XLVX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656078673","title":"ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656078673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656078673?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787500,"startTime":"0","endTime":"0","summary":"Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337877/0/en/ORIC-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Operational-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","BK4213","MEDX","AR","HYLG","LNGX","BK4139","IDNA","ORIC","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656036803","title":"Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2656036803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656036803?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:32","pubTimestamp":1785774763,"startTime":"0","endTime":"0","summary":"Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. Xencor, Inc. is running a Phase 1 clinical trial called “A Phase 1, First-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xencors-xmab412-enters-first-in-human-testing-what-early-stage-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xencors-xmab412-enters-first-in-human-testing-what-early-stage-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","HYLG","IDNA","NVIB","ISBC","BK4211","XNCR","BK4139","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379121","title":"AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379121","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379121?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:33","pubTimestamp":1785760380,"startTime":"0","endTime":"0","summary":"Milestone Advances Ampligen Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027OCALA, Fla., Aug.  03, 2026  (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE Ame","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337516/29489/en/AIM-ImmunoTech-Ahead-of-Schedule-on-Last-Dose-DURIPANC-Critical-Clinical-Inflection-Point.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","HYLG","NVIB","GDOC","MEDX","BK4139","BK4557","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379644","title":"Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379644","media":"Dow Jones","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379644?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:30","pubTimestamp":1785760200,"startTime":"0","endTime":"0","summary":"BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","CUE","BK4022","BK4232","NVIB","BK4139","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379177","title":"Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379177?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:30","pubTimestamp":1785760200,"startTime":"0","endTime":"0","summary":"MIAMI, FL, Aug.  03, 2026  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337496/11676/en/Veru-to-Report-Fiscal-2026-Third-Quarter-Financial-Results-on-August-10th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","VERU","NVIB","MEDX","IDNA","BK4183","BK4007","HYLG","BK4557","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656766333","title":"Press Release: Design Therapeutics Provides Restore-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2656766333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656766333?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:00","pubTimestamp":1785758400,"startTime":"0","endTime":"0","summary":"RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1Cash and securities of $207.4 million at quarter-end provide strong financial runwayCARLSBAD, Calif., Aug. 03, 2026  -- Design Therapeutics, Inc. , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC portfolio.\"Design continued its strong operational execution in the second quarter building on the positive RESTORE-FA data reported in May. Those four-week data demonstrated the ability of DT-216P2 to increase endogenous frataxin and its potential to deliver a differentiated, best-in-disease therapy for Friedreich ataxia,\" said Pratik Shah, Ph.D., chairperson and chief ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HD","IE00BSNM7G36.USD","IE00BWXC8680.SGD","IE00B3T34201.USD","IE00BKVL7J92.USD","LU0868494708.USD","LU0820561818.USD","LU0238689110.USD","LU1093756325.SGD","BK4581","BK4566","MEDX","LU2756315318.SGD","PKB","LU2361045086.USD","HOMZ","BK4130","LU1929549753.HKD","LU1093756168.USD","LU1035775433.USD","IDNA","LU2461242641.AUD","NVIB","LU0079474960.USD","DSGN","BK4550","SG9999001440.SGD","LU1496350171.SGD","IE00BZ1G4Q59.USD","LU1914381329.SGD","LU0868494617.USD","IE00B1XK9C88.USD","BK4022","GDOC","LU0234572021.USD","LU0689472784.USD","LU1236620834.HKD","BK4585","BK4083","LU1551013342.USD","LU0823434740.USD","RTH","FA","R","LU2756315664.SGD","LU1069344957.HKD","LU0820562030.AUD","LU2361044865.SGD","LU1162221912.USD","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656457133","title":"Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2656457133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656457133?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:42","pubTimestamp":1785710561,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an announcement. Recce Pharmaceuticals Ltd., an Australian biotech company listed on the ASX...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recce-pharmaceuticals-seeks-asx-quotation-for-advisory-fee-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recce-pharmaceuticals-seeks-asx-quotation-for-advisory-fee-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368936","title":"Press Release: Radiopharm Theranostics Reports Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368936?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:00","pubTimestamp":1785495600,"startTime":"0","endTime":"0","summary":"endpoint, with 93% of patients treated with RAD 101 achieving concordance. with MRI imaging. Additionally, an interim analysis of 14 patients from. -- The Company anticipates the initiation of a Phase 3, multi-center,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","RAD.AU","BK4139","NVIB","ODD","HYLG","BK7067","BK4183","IE0009354923.USD","IDNA","RADX","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655357622","title":"Shenzhen Chipscreen Biosciences Gets China Clinical Trial Approval for Leukemia Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2655357622","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655357622?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:19","pubTimestamp":1785493195,"startTime":"0","endTime":"0","summary":"Shenzhen Chipscreen Biosciences  received clinical trial approval from China's National Medical Products Administration for its self-developed CS43158 tablets, according to a Friday filing with the Shanghai Stock Exchange.The drug, approved for domestic clinical trials in China, is indicated for acute myeloid leukemia.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688321","GDOC","HYLG","NVIB","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655035713","title":"Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2655035713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655035713?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:12","pubTimestamp":1785492749,"startTime":"0","endTime":"0","summary":"An update from N4 Pharma ( ($GB:THAT) ) is now available. Thalia Therapeutics plc, an AIM-listed clinical-stage biotech specialising in RNA-based t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","BK4588","BK4585","NVIB","IE0009354923.USD","BBC","XBIX","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655030638","title":"PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2655030638","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655030638?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:00","pubTimestamp":1785420050,"startTime":"0","endTime":"0","summary":"“PharmAla’s (MDXXF) financial position continues to improve compared to 2025, in line with the broader growth of the biotech industry,” said Nick K...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharmala-reports-q3-revenue-c513000-vs-c135000-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharmala-reports-q3-revenue-c513000-vs-c135000-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","MDXXF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655803050","title":"Clearmind Medicine announces safety results from Part A of CMND-100 tral","url":"https://stock-news.laohu8.com/highlight/detail?id=2655803050","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655803050?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:45","pubTimestamp":1785419153,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced safety results from Part A of its ongoing FDA-regulated Phase I/II clinical trial evaluating CMND-100, the comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-safety-results-from-part-a-of-cmnd-100-tral-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-safety-results-from-part-a-of-cmnd-100-tral-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","NVIB","GDOC","BK4588","BK4007","CMND","IDNA","HYLG","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655808400","title":"Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655808400","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655808400?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:30","pubTimestamp":1785414600,"startTime":"0","endTime":"0","summary":"REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3336054/0/en/Newly-FDA-Approved-REVTORPYK-gedatolisib-Included-in-the-National-Comprehensive-Cancer-Network-NCCN-Clinical-Practice-Guidelines-for-HR-HER2-Locally-Advanced-or-Metastatic-Breast-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","MEDX","BK4225","AEIS","HR","IE00B19Z4B17.USD","BK4139","GDOC","LABU","IE00B66KJ199.SGD","SRET","NVIB","BK4599","LU1815336091.USD","BK4157","IE00B7SZL793.SGD","IDNA","IE0031619046.USD","ALT","BK4203","NHLD","HYLG","BK4585","LU1878469433.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":105,"code":"91000000","status":"200"}]}}